On a corporate action affecting ordinary shares of Avidity Biosciences, Inc. (RNA)

On October 25, 2025, Avidity Biosciences, Inc. entered into a merger agreement under which Novartis AG will acquire Avidity Biosciences, Inc. Avidity Biosciences, Inc. stockholders will receive $72.00 in cash for each share of Avidity Biosciences, Inc. that they own.

Prior to the closing of the merger, Avidity Biosciences, Inc. plans to spin off its early-stage precision cardiology programs into a new independent publicly traded company, Atrium Therapeutics, Inc. Avidity Biosciences, Inc. stockholders will receive one share of Atrium Therapeutics, Inc. for every ten shares of Avidity Biosciences, Inc. that they own.

Transactions are expected to close in the first half of 2026 if approved by stockholders on the Special Meeting of Stockholders to be held on February 23, 2026. For more details, please, refer to the company’s website.  

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.